Evidence map›Paper›PMID 26382223›Full record

ArticleClinical genitourinary cancer2016

Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer.

Michaela A Dinan, Yanhong Li, Yinghong Zhang, Suzanne B Stewart, Lesley H Curtis, Daniel J George, Shelby D Reed

Abstract read
In one paragraph

Article in Clinical genitourinary cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2021
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Michaela A DinanDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Duke Cancer Institute, Duke University School of Medicine, Durham, NC; Department of Medicine, Duke University School of Medicine, Durham, NC. Electronic address: michaela.dinan@duke.edu.
Yanhong LiDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Yinghong ZhangDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Suzanne B StewartDepartment of Medicine, Duke University School of Medicine, Durham, NC; Department of Surgery, Duke University School of Medicine, Durham, NC.
Lesley H CurtisDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Department of Medicine, Duke University School of Medicine, Durham, NC.
Daniel J GeorgeDuke Cancer Institute, Duke University School of Medicine, Durham, NC; Department of Surgery, Duke University School of Medicine, Durham, NC.
Shelby D ReedDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Duke Cancer Institute, Duke University School of Medicine, Durham, NC; Department of Medicine, Duke University School of Medicine, Durham, NC.

Funding

Clinical validity and utility of genomic targeted chemoprevention of PCaRC2CA148463 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI XU, JIANFENG · 2009 to 2009
$2.0M
National Utilization Patterns of Oncotype DX in Early Stage Breast CancerK99HS022189 · AHRQ · DUKE UNIVERSITY · PI DINAN, MICHAELA ANN · 2013 to 2014
$271k
AHRQ HHS K99 HS022189AHRQ HHS K99HS022189NCI NIH HHS RC2 CA148463NCI NIH HHS RC2CA148463
6 · The paper itself

Abstract

unlabelledWe conducted a retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data of men with prostate cancer. Among 34,727 patients, those who died of their prostate cancer had more hospice and outpatient use, less inpatient and intensive care unit use, and lower overall costs. Efforts to shift care toward the outpatient setting might provide more efficient and judicious care for patients during the end of life.

backgroundProstate cancer poses a significant financial burden in the United States. However, most men with prostate cancer will die from noncancer causes. Concerns about increased resource utilization at the end of life have not been appropriately examined in this context. MATERIALS AND

methodsWe conducted a retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data of men who were diagnosed with and died of, as opposed to with, prostate cancer between 2000 and 2007. Within these 2 populations, we compared changes in the use of medical interventions, hospice, and overall health care costs to Medicare in the last year of life.

resultsAmong 34,727 patients, those who died of prostate cancer had lower costs ($43,572 vs. $45,830; P < .001), largely because of lower mean inpatient costs ($20,769 vs. $29,851) and fewer hospitalizations (1.8 vs. 2.1), inpatient days (12.2 vs. 15.7), intensive care unit (ICU) days (1.4 vs. 3.4), and skilled nursing facility days (11.7 vs. 14.7; P < .001 for all). Outpatient and hospice costs were significantly greater among patients who died of prostate cancer, as was use of chemotherapy and androgen deprivation therapy. Patients who died of prostate cancer had approximately 12% lower costs than patients who died from other causes in adjusted analyses (fold-change, 0.88; 95% confidence interval [CI], 0.85-0.92). The single strongest predictor of increased costs at the end of life was receipt of multiple invasive procedures (fold increase in costs, 2.39; 95% CI, 2.22-2.58).

conclusionPatients who died of prostate cancer rather than from other causes had more hospice and outpatient use, less inpatient and ICU use, and lower overall costs. Efforts to shift care toward outpatient settings might provide more efficient and judicious care for patients during the end of life.

Indexed as

Cost of IllnessAgedAged, 80 and overHealth Care CostsHealth ResourcesHospice CareHospitalizationHumansMaleMedicareProstatic NeoplasmsRetrospective StudiesSEER ProgramUnited StatesHealth care costsMedicareProstatic neoplasmSEER ProgramTerminal care

Identifiers

PMID26382223
PMCPMC4698191

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.